Potential Benefits of Computer-Aided Detection for Cancer Identification and Treatment.

Abstract

were not associated with the change in overall cognition compound scores (mean [standard error], -0.003 [0.10]; -0.06 [0.09]; and 0.05 [0.10], respectively; P = .29). The effect of the intervention was further explored by performing stratified analyses by median PP. In the 178 patients with a higher baseline PP (>64.8 mm Hg; ie, increased arterial stiffness), the discontinuation of antihypertensive treatment group did not differ from the continuation group in change in overall cognition compound score (difference, -0.07; 95% CI, −0.37 to 0.24;P = .68). Furthermore, analyses restricted to the discontinuation group (n = 180) showed that tertiles of the change in PP were not related to the change in overall cognition compound score (β = -0.10; 95% CI, −0.26 to 0.07; P = .24). A possible explanation for the absence of any association between PP and cognitive function in the DANTE study Leiden 1 is that persons with serious cardiovascular disease were excluded, resulting in a population with limited arterial stiffness. Also, several studies indicated that chronic kidney disease (CKD) is an independent predictor for cognitive impairment. 3 As estimated glomerular filtration rate was not assessed in the DANTE Study Leiden, 1 it was not possible to perform additional analyses regarding its association with cognitive function. Moreover, patients with CKD were excluded from participation, as discontinuation of antihypertensive treatment may have adverse effects on the progression of CKD. 4 Similarly, in other major trials 5 with cardiovascular interventions, patients with CKD are underrepresented despite the high prevalence of CKD in the general population and the growing need for high-quality evidence within this group.